Pushkal Garg Sells 52,592 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Stock

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) CMO Pushkal Garg sold 52,592 shares of the firm’s stock in a transaction on Monday, January 27th. The stock was sold at an average price of $285.00, for a total value of $14,988,720.00. Following the completion of the sale, the chief marketing officer now directly owns 11,989 shares of the company’s stock, valued at $3,416,865. The trade was a 81.44 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Pushkal Garg also recently made the following trade(s):

• On Thursday, December 12th, Pushkal Garg sold 1,752 shares of Alnylam Pharmaceuticals stock. The stock was sold at an average price of $251.00, for a total value of $439,752.00.
• On Tuesday, November 26th, Pushkal Garg sold 1,682 shares of Alnylam Pharmaceuticals stock. The shares were sold at an average price of $250.98, for a total transaction of $422,148.36.

Alnylam Pharmaceuticals Trading Down 1.9 %

Shares of Alnylam Pharmaceuticals stock opened at $273.99 on Thursday. Alnylam Pharmaceuticals, Inc. has a twelve month low of $141.98 and a twelve month high of $304.39. The firm’s 50-day moving average price is $249.42 and its 200 day moving average price is $260.65. The company has a current ratio of 2.75, a quick ratio of 2.69 and a debt-to-equity ratio of 31.64. The firm has a market capitalization of $35.34 billion, a PE ratio of -104.58 and a beta of 0.34.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings results on Thursday, October 31st. The biopharmaceutical company reported ($0.87) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.36). The firm had revenue of $500.90 million during the quarter, compared to analysts’ expectations of $532.91 million. During the same quarter in the previous year, the company earned $1.15 earnings per share. Alnylam Pharmaceuticals’s revenue was down 33.3% on a year-over-year basis. On average, sell-side analysts predict that Alnylam Pharmaceuticals, Inc. will post -2.24 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Huntington National Bank lifted its stake in shares of Alnylam Pharmaceuticals by 91.8% in the third quarter. Huntington National Bank now owns 94 shares of the biopharmaceutical company’s stock worth $26,000 after buying an additional 45 shares in the last quarter. Hollencrest Capital Management acquired a new stake in Alnylam Pharmaceuticals in the 3rd quarter valued at about $29,000. R Squared Ltd purchased a new position in Alnylam Pharmaceuticals in the 4th quarter worth approximately $33,000. Washington Trust Advisors Inc. acquired a new position in shares of Alnylam Pharmaceuticals during the 3rd quarter worth approximately $42,000. Finally, True Wealth Design LLC grew its position in shares of Alnylam Pharmaceuticals by 15,300.0% in the third quarter. True Wealth Design LLC now owns 154 shares of the biopharmaceutical company’s stock valued at $42,000 after purchasing an additional 153 shares in the last quarter. Hedge funds and other institutional investors own 92.97% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have issued reports on ALNY shares. Barclays upped their price target on shares of Alnylam Pharmaceuticals from $295.00 to $329.00 and gave the company an “overweight” rating in a research note on Friday, November 1st. William Blair reissued an “outperform” rating on shares of Alnylam Pharmaceuticals in a report on Tuesday, November 19th. Bank of America lifted their target price on Alnylam Pharmaceuticals from $307.00 to $314.00 and gave the stock a “buy” rating in a report on Monday, October 14th. Needham & Company LLC reiterated a “buy” rating and issued a $320.00 price target on shares of Alnylam Pharmaceuticals in a report on Monday, January 13th. Finally, Scotiabank lifted their price objective on shares of Alnylam Pharmaceuticals from $305.00 to $310.00 and gave the company a “sector outperform” rating in a research note on Friday, November 1st. One analyst has rated the stock with a sell rating, six have assigned a hold rating and nineteen have given a buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $298.61.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.